<DOC>
	<DOCNO>NCT01232881</DOCNO>
	<brief_summary>This tumor serum collection study patient advance breast cancer receive treatment lonafarnib .</brief_summary>
	<brief_title>Predicting Response Toxicity Patients Receiving Lonafarnib Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Sample Collection : - Tumor sample - Serum sample Treatment Regimen : - All registered patient must plan treatment lonafarnib</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Written inform consent HIPAA authorization release personal health information . NOTE : HIPAA authorization may include informed consent obtain separately . Age &gt; 18 year . Planned treatment lonafarnib metastatic breast cancer . Must consent biopsy perform obtain fresh tissue able identify formalin fix paraffin embed ( FFPE ) tissue block tumor sample obtain complete test study . Planned treatment treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>